355 related articles for article (PubMed ID: 26469193)
1. Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients.
van der Hulle T; den Exter PL; Planquette B; Meyer G; Soler S; Monreal M; Jiménez D; Portillo AK; O'Connell C; Liebman HA; Shteinberg M; Adir Y; Tiseo M; Bersanelli M; Abdel-Razeq HN; Mansour AH; Donnelly OG; Radhakrishna G; Ramasamy S; Bozas G; Maraveyas A; Shinagare AB; Hatabu H; Nishino M; Huisman MV; Klok FA
J Thromb Haemost; 2016 Jan; 14(1):105-13. PubMed ID: 26469193
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
[TBL] [Abstract][Full Text] [Related]
3. Unreported incidental pulmonary embolism in patients with cancer: Radiologic natural history and risk of recurrent venous thromboembolism and death.
Wiklund P; Medson K; Elf J
Thromb Res; 2023 Apr; 224():65-72. PubMed ID: 36867992
[TBL] [Abstract][Full Text] [Related]
4. Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
Andras A; Sala Tenna A; Stewart M
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002001. PubMed ID: 28737834
[TBL] [Abstract][Full Text] [Related]
5. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
[TBL] [Abstract][Full Text] [Related]
6. Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study.
Kraaijpoel N; Bleker SM; Meyer G; Mahé I; Muñoz A; Bertoletti L; Bartels-Rutten A; Beyer-Westendorf J; Porreca E; Boulon C; van Es N; Iosub DI; Couturaud F; Biosca M; Lerede T; Lacroix P; Maraveyas A; Aggarwal A; Girard P; Büller HR; Di Nisio M;
J Clin Oncol; 2019 Jul; 37(20):1713-1720. PubMed ID: 31116676
[TBL] [Abstract][Full Text] [Related]
7. Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. An Observational Study in Routine Clinical Practice.
den Exter PL; Hooijer J; van der Hulle T; van Oosten JP; Dekkers OM; Klok FA; Huisman MV
Thromb Haemost; 2017 Nov; 117(11):2163-2167. PubMed ID: 28981552
[TBL] [Abstract][Full Text] [Related]
8. Incidentally Diagnosed With Pulmonary Embolism in Lung Cancer Patients: Comparison of Clinical Characteristics and Mortality With Symptomatic Pulmonary Embolism.
Luo Z; Xu N; Ma G; Lu Y; Yao J; Ying K
Clin Appl Thromb Hemost; 2023; 29():10760296231212482. PubMed ID: 37981734
[TBL] [Abstract][Full Text] [Related]
9. Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancer-associated venous thromboembolism during anticoagulant treatment.
Kooiman J; den Exter PL; Cannegieter SC; le Cessie S; del Toro J; Sahuquillo JC; Pedrajas JM; Huisman MV
J Thromb Haemost; 2013 Nov; 11(11):1968-76. PubMed ID: 24112123
[TBL] [Abstract][Full Text] [Related]
10. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients.
den Exter PL; Hooijer J; Dekkers OM; Huisman MV
J Clin Oncol; 2011 Jun; 29(17):2405-9. PubMed ID: 21555690
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials.
Louzada ML; Majeed H; Wells PS
Thromb Res; 2009 Apr; 123(6):837-44. PubMed ID: 18977517
[TBL] [Abstract][Full Text] [Related]
13. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.
Kirkilesis GI; Kakkos SK; Tsolakis IA
Eur J Vasc Endovasc Surg; 2019 May; 57(5):685-701. PubMed ID: 31097186
[TBL] [Abstract][Full Text] [Related]
14. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation for people with cancer and central venous catheters.
Kahale LA; Tsolakian IG; Hakoum MB; Matar CF; Barba M; Yosuico VE; Terrenato I; Sperati F; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006468. PubMed ID: 29856471
[TBL] [Abstract][Full Text] [Related]
16. Incidental pulmonary embolism in cancer and noncancer patients: Prospective cohort study.
Wysokinska EM; Houghton DE; Vlazny DT; Ashrani AA; Froehling DA; Meverden R; Hodge DO; Peterson LG; McBane RD; Wysokinski WE; Casanegra AI
Eur J Haematol; 2023 Jan; 110(1):88-98. PubMed ID: 36210612
[TBL] [Abstract][Full Text] [Related]
17. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism.
Chai-Adisaksopha C; Iorio A; Crowther MA; de Miguel J; Salgado E; Zdraveska M; Fernández-Capitán C; Nieto JA; Barillari G; Bertoletti L; Monreal M;
Am J Med; 2018 Apr; 131(4):430-437. PubMed ID: 29274307
[TBL] [Abstract][Full Text] [Related]
18. Long-term therapy with low-molecular-weight heparin in cancer patients with venous thromboembolism.
Marchena PJ; Nieto JA; Guil M; García-Bragado F; Rabuñal R; Boccalon H; Trujillo-Santos J; Monreal M;
Thromb Haemost; 2012 Jan; 107(1):37-43. PubMed ID: 22116496
[TBL] [Abstract][Full Text] [Related]
19. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.
Schulman S; Zondag M; Linkins L; Pasca S; Cheung YW; de Sancho M; Gallus A; Lecumberri R; Molnar S; Ageno W; Le Gal G; Falanga A; Hulegårdh E; Ranta S; Kamphuisen P; Debourdeau P; Rigamonti V; Ortel TL; Lee A
J Thromb Haemost; 2015 Jun; 13(6):1010-8. PubMed ID: 25851122
[TBL] [Abstract][Full Text] [Related]
20. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
Andras A; Sala Tenna A; Crawford F
Cochrane Database Syst Rev; 2012 Oct; 10():CD002001. PubMed ID: 23076894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
